Your browser doesn't support javascript.
loading
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels, Kamrine E; Schoenfeld, Adam J; Makhnin, Alex; Tobi, Yosef; Wang, Yuli; Frisco-Cabanos, Heidie; Chakrabarti, Shaon; Shi, Manli; Napoli, Chelsi; McDonald, Thomas O; Tan, Weiwei; Hata, Aaron; Weinrich, Scott L; Yu, Helena A; Michor, Franziska.
Afiliação
  • Poels KE; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Schoenfeld AJ; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • Makhnin A; Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
  • Tobi Y; Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
  • Wang Y; Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
  • Frisco-Cabanos H; Oncology Research and Development, Pfizer Inc, La Jolla, CA, USA.
  • Chakrabarti S; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Shi M; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Napoli C; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • McDonald TO; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
  • Tan W; Oncology Research and Development, Pfizer Inc, La Jolla, CA, USA.
  • Hata A; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Weinrich SL; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Yu HA; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • Michor F; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Nat Commun ; 12(1): 3697, 2021 06 17.
Article em En | MEDLINE | ID: mdl-34140482
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Quinazolinonas / Compostos de Anilina / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Quinazolinonas / Compostos de Anilina / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article